Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

Ad26.COV2.S 启动为基于 mRNA 的 COVID-19 加强疫苗接种提供了坚实的免疫学基础

阅读:19
作者:Daryl Geers, Roos S G Sablerolles, Debbie van Baarle, Neeltje A Kootstra, Wim J R Rietdijk, Katharina S Schmitz, Lennert Gommers, Susanne Bogers, Nella J Nieuwkoop, Laura L A van Dijk, Eva van Haren, Melvin Lafeber, Virgil A S H Dalm, Abraham Goorhuis, Douwe F Postma, Leo G Visser, Anke L W Huckried

Abstract

The emergence of novel SARS-CoV-2 variants led to the recommendation of booster vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster vaccination induces high antibody levels, but how heterologous boosters affect other functional aspects of the immune response remained unknown. Here, we performed immunological profiling of Ad26.COV2.S-primed individuals before and after homologous or heterologous (mRNA-1273 or BNT162b2) booster. Booster vaccinations increased functional antibodies targeting ancestral SARS-CoV-2 and emerging variants. Especially heterologous booster vaccinations induced high levels of functional antibodies. In contrast, T-cell responses were similar in magnitude following homologous or heterologous booster vaccination and retained cross-reactivity towards variants. Booster vaccination led to a minimal expansion of SARS-CoV-2-specific T-cell clones and no increase in the breadth of the T-cell repertoire. In conclusion, we show that Ad26.COV2.S priming vaccination provided a solid immunological base for heterologous boosting, increasing humoral and cellular responses targeting emerging variants of concern.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。